Benzyl 3,4-difluorobenzoate | 241160-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl 3,4-difluorobenzoate
• CAS: 241160-17-8
• 化学式: C₁₄H₁₀F₂O₂
• 分子量: 248.22
• InChiKey: DMEWAYORULOFPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] NOVEL PqsR INVERSE AGONISTS<br/>[FR] NOUVEAUX AGONISTES INVERSES DE PQSR
  申请人：HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH

  公开号：WO2021136805A1

  公开（公告）日：2021-07-08

  The present invention relates to a compound according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention: to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.

  本发明涉及一种化合物，其通式为（I），作为PqsR的反向激动剂（目前已知的Pseudomonas Quinolone Signal（PQS）受体，有时也称为MvfR）；一种含有该化合物的药物组合物；至少包含本发明化合物之一和至少一种其他活性药物成分的组合制剂；以及该化合物的用途，包括作为药物的用途，例如用于治疗或预防细菌感染，特别是铜绿假单胞菌或伯克霍尔德氏菌感染。
• 3,6-ketal and enol ether macrolide antibiotics
  申请人：Pfizer Products Inc.

  公开号：EP0941998A2

  公开（公告）日：1999-09-15

  This invention relates to compounds of formulas 1 and 2    and to pharmaceutically acceptable salts and solvates thereof, wherein X, X1, R1, R2, R7, R17 and R19 are as defined herein. The compounds of formulas 1 and 2 may be useful in the treatment of bacterial, parasitic and protozoal infections, as well as disorders related to bacterial, parasitic and protozoal infections, in mammals, fish and birds. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and 2 and to methods of treating bacterial, parasitic and protozoal infections by administering the compounds of formula 1 and 2.

  本发明涉及式 1 和 2 的化合物 及其药学上可接受的盐和溶液，其中 X、X1、R1、R2、R7、R17 和 R19 如本文所定义。式 1 和 2 的化合物可用于治疗哺乳动物、鱼类和鸟类的细菌、寄生虫和原生动物感染，以及与细菌、寄生虫和原生动物感染有关的疾病。本发明还涉及含有式 1 和 2 化合物的药物组合物，以及通过施用式 1 和 2 化合物治疗细菌、寄生虫和原生动物感染的方法。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3798214A1

  公开（公告）日：2021-03-31

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明的特征是一种式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、W、X、Y、Z、n、o、p 和 q 在本文中定义，用于治疗 CFTR 介导的疾病，如囊性纤维化。本发明还包括药物组合物、治疗方法及其试剂盒。
• 3,6-ketal macrolide antibiotics
  申请人：Pfizer Products Inc.

  公开号：EP0941998B1

  公开（公告）日：2004-09-01
• ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFN
  申请人：Bristol-Myers Squibb Company

  公开号：EP2917186B1

  公开（公告）日：2017-10-18